Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 58.50
-2.45 (-4.02%)
Sep 10, 2026, 11:57 AM HKT
HKG:2315 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,699 | 1,379 | 980.45 | 716.91 | 533.88 | 354.56 |
Revenue Growth | 42.68% | 40.63% | 36.76% | 34.28% | 50.58% | 39.84% |
Gross Profit Gross Profit Growth | 1,336 | 1,030 | 755.39 | 510.91 | 395.67 | 257.25 |
Operating Income Operating Income Growth | 423.85 | 211.22 | 131.22 | -291.5 | -604.6 | -519.07 |
Net Income Net Income Growth | 366.3 | 173.2 | 33.54 | -382.95 | -601.95 | -545.58 |
Earnings Per Share EPS Growth | 0.86 | 0.43 | 0.08 | -0.96 | -1.58 | -1.51 |
EPS Growth | 171.76% | 437.50% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 |
|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 |
Gene Editing Gene Editing Growth | 77.76 | 72.02 |
Pre-Clinical Pharmacology and Efficacy Evaluation Pre-Clinical Pharmacology and Efficacy Evaluation Growth | 440.53 | 352.2 |
Disease Models Selling Disease Models Selling Growth | 878.48 | 675.62 |
Antibody Development Antibody Development Growth | 387.35 | 332.35 |
Others Others Growth | 0.06 | 0.05 |
Elimination of Inter-Segment Elimination of Inter-Segment Growth | -84.95 | -53.44 |
Total Total Growth | 1,699 | 1,379 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,053 | 1,585 | 403.85 | 434.04 | 643.97 | 573.42 |
Total Debt Total Debt Growth | 693.49 | 584.09 | 570.28 | 544.11 | 415.28 | 89.8 |
Net Cash (Debt) Net Cash Growth | 359.54 | 1,001 | -166.43 | -110.07 | 228.69 | 483.62 |
Net Cash Growth | - | - | - | - | -52.71% | -44.82% |
Net Cash Per Share Net Cash Per Share Growth | 0.84 | 2.49 | -0.40 | -0.28 | 0.60 | 1.33 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 428.38 | 370.25 | 211.25 | -76.65 | -303.27 | -365.78 |
Capital Expenditures CapEx Growth | -276.74 | -87.82 | -37.13 | -126.62 | -240.27 | -198.67 |
Free Cash Flow Free Cash Flow Growth | 151.64 | 282.43 | 174.12 | -203.26 | -543.54 | -564.45 |
Free Cash Flow Growth | -55.22% | 62.21% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 78.60% | 74.72% | 77.04% | 71.27% | 74.11% | 72.56% |
Operating Margin | 24.94% | 15.32% | 13.38% | -40.66% | -113.25% | -146.40% |
Pretax Margin | 22.19% | 13.64% | 4.38% | -53.03% | -112.64% | -153.90% |
Profit Margin | 21.56% | 12.56% | 3.42% | -53.42% | -112.75% | -153.88% |
FCF Margin | 8.92% | 20.48% | 17.76% | -28.35% | -101.81% | -159.20% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 61.46 | 122.37 | 95.11 | - | - | - |
Forward PE | 60.65 | 49.96 | - | - | - | - |
P/FCF Ratio | 321.30 | 75.04 | 18.32 | - | - | - |
PS Ratio | 28.67 | 15.37 | 3.25 | 6.06 | 16.97 | - |